
Core Insights - BriaCell Therapeutics Corp. is conducting a pivotal Phase 3 clinical study for its lead candidate, Bria-IMT, in advanced metastatic breast cancer, with over 75 patients enrolled and more than 100 consented [1][2][9] - The company expects to complete patient enrollment by late 2025 or early 2026 and may report top-line data as early as the first half of 2026 [1][5] - The study is being conducted at 54 clinical sites across 15 states in the US, with a focus on evaluating overall survival compared to physician's choice treatment [4][5][9] Company Statements - Dr. William V. Williams, President & CEO, expressed optimism about the expanding patient enrollment and the potential of Bria-IMT to transform cancer care for metastatic breast cancer patients [3] - Dr. Giuseppe Del Priore, Chief Medical Officer, noted that the enrollment pace and clinical investigator interest are higher than previously observed, highlighting the dedication of clinical investigators and patients [3] Study Details - The primary endpoint of the study is overall survival, with interim data analysis planned once 144 patient events occur [5] - The Bria-IMT combination regimen has received FDA Fast Track designation, indicating its potential for expedited development and review [5] - Positive results from the Phase 3 study could lead to full approval and marketing authorization for Bria-IMT in metastatic breast cancer patients [5]